Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 4/20 | 0.45 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 8/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11894984 | 0.93 | PTGES (0.47) | PTGESMALT1JAK1TP53HDAC6 | |
| SCHEMBL15380924 | 0.88 | HDAC6 (0.42) | PTGESTP53HDAC6LMNAPOLB | |
| SCHEMBL15380913 | 0.87 | KMT2A (0.46) | PTGES | |
| SCHEMBL3094243 | 0.86 | IDH1 (0.44) | PTGES | |
| SCHEMBL3100803 | 0.84 | PTGES (0.54) | PTGESHDAC6KCNH2CCR3 | |
| SCHEMBL3109449 | 0.84 | PTGES (0.54) | PTGESHDAC6KCNH2CCR3 | |
| SCHEMBL3111197 | 0.83 | PTGES (0.54) | PTGESHDAC6KCNH2CCR3 | |
| SCHEMBL3106626 | 0.81 | PTGES (0.52) | PTGESTP53HDAC6LMNAKCNH2 | |
| SCHEMBL3101879 | 0.81 | PTGES (0.47) | PTGESPOLB | |
| SCHEMBL3099237 | 0.80 | PTGES (0.46) | PTGESTP53POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921405-B2 | Compounds | OREXO AB (SE) | 2014-12-30 | — | — | US | disclosed |
| US-20130303571-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303571-A1 | NEW COMPOUNDS | MTX1, LTB4R, RDX | PTGES 307/4885MALT1 1129/4885JAK1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.